12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cabozantinib: Additional Phase II data

Additional interim data from 41 evaluable patients in the cohort of subjects with hepatocellular carcinoma (HCC) in the lead-in stage of an adaptive, international Phase II trial showed that once-daily oral cabozantinib led to a median overall survival (OS) of 15.1 months. In the lead-in stage of the study, patients receive once-daily 100 mg cabozantinib for 12 weeks. Patients who achieve a partial response continue open-label cabozantinib, patients with progressive disease discontinue treatment...

Read the full 344 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >